← All organizations
Highest phase reached
Phase 2
First clinical trial
May 23, 2018Last known activity
Nov 30, 2025
Timeline
No events for the selected filters.
Drugs by trial phase (27 distinct, 46 trials)
Phase 2 (6 own, 0 via acquisition)
Phase 1 (21 own, 0 via acquisition)
- cyclophosphamide
- cd33 car-t cells
- fludarabine
- gd2 car t cells
- cd20/cd22 targeted car t-cells
- ciltacabtagene autoleucel
- autologous hematopoietic stem cells
- cd38 car-t cells
- nkg2d car-t cell
- cd117 car-t cells
- cll-1.car t cells
- bcma/cd19 dual-target car-t
- murine cd19 car-t cells
- cd5 car-t cells
- il3 car-t cells
- +6 more
Indications
Recent trials (46)
- NCT07252336CollaboratorPhase 2Nov 30, 2025
- NCT07144020CollaboratorEarly Phase 1Sep 5, 2025
- NCT06787560CollaboratorEarly Phase 1Jan 31, 2025
- NCT06793241CollaboratorEarly Phase 1Jan 31, 2025
- NCT06785519CollaboratorEarly Phase 1Jan 31, 2025
- NCT06769191CollaboratorEarly Phase 1Jan 30, 2025
- NCT06762132CollaboratorEarly Phase 1Jan 10, 2025
- NCT06684639CollaboratorEarly Phase 1Dec 1, 2024
- NCT06633354CollaboratorEarly Phase 1Oct 20, 2024
- NCT06633341CollaboratorEarly Phase 1Oct 20, 2024
- NCT06633328CollaboratorEarly Phase 1Oct 20, 2024
- NCT06346912CollaboratorEarly Phase 1May 30, 2024
- NCT06279923CollaboratorEarly Phase 1Apr 15, 2024
- NCT06132711CollaboratorPhase 1/Phase 2Nov 10, 2023
- NCT06084962CollaboratorPhase 1Oct 20, 2023
Details
- Last known activity
- Nov 30, 2025